retatrutide type 2 diabetes trial results 2024 2025 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase This data from Phase 3

When adjunctive therapy is being considered, several factors, including the route of administration, the adverse-effect profile, patient preference, and cost, should be evaluated

Ozempic face, which happens when theres rapid loss of fat in the face, and might cause sunken eyes, hollow appearance, wrinkles, or sagging

Health Canada also warned about these risks, as well as the potential for mood swings, blood sugar imbalances, liver or kidney damage, and blood clots

10.1111/j.1464-5491.2010.02938.x 28

Crosstalk between immune cells, the enteric nervous system, L-cells, and other enteroendocrine subtypes is an area of physiology ripe for discovery